Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)

INTRODUCTION: A diagnosis of type 2 diabetes (T2D) more than doubles the risk of cardiovascular disease (CVD), with heart failure (HF) being one of the most common complications with a severe prognosis. The landmark Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Paitien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jürgens, Mikkel, Schou, Morten, Hasbak, Philip, Kjær, Andreas, Wolsk, Emil, Zerahn, Bo, Wiberg, Mikkel, Brandt, Niels Høgh, Gæde, Peter Haulund, Rossing, Peter, Faber, Jens, Inzucchi, Silvio, Gustafsson, Finn, Kistorp, Caroline Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887087/
https://www.ncbi.nlm.nih.gov/pubmed/31780586
http://dx.doi.org/10.1136/bmjopen-2019-029098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887087/
https://www.ncbi.nlm.nih.gov/pubmed/31780586
http://dx.doi.org/10.1136/bmjopen-2019-029098

Ejemplares similares